|
Paul Herrling is Head of Corporate Research at Novartis, a position he assumed in November 2002. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases (NITD) in Singapore, a long-term endeavor to advance medical research in tropical infectious diseases, which historically have received little drug-research funding. In addition, he oversees the Friedrich Miescher Institute (FMI) in Basel, Switzerland and the Genomics Institute of the Novartis Research Foundation in California, USA.
Prior to his current position, Paul Herrling was Head of Global Research of Novartis Pharma and a member of the Pharma Executive Committee (PEC). In this capacity, he directed the integration of the research organizations of Sandoz and Ciba-Geigy following their merger in 1996 to form Novartis.
Paul Herrling joined Sandoz Pharma in 1975 and held various positions in research at both Sandoz in Basel, Switzerland and Wander in Bern, Switzerland. In 1985, he became Head of the Sandoz Research Institute in Bern and Head of the Preclinical CNS Research Department at Sandoz Pharma in Basel. In 1992, he was made Head of Preclinical Research Basel for Sandoz Pharma and, in 1994, Head of Corporate Research.
He is also a Professor of Drug Discovery Science at the University of Basel, Switzerland. In addition to scientific editing activities, he serves on several boards, most notably Board of Trustees of The Scripps Research Institute, the Board of the ETH (Swiss Federal Institutes of Technology) and the Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative (DNDi).
Paul Herrling obtained his Ph.D. in 1975 from the University of Zurich, Switzerland and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA) in the USA. | 